Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with rheumatic diseases

Clin Exp Immunol. 1992 Feb;87(2):178-82. doi: 10.1111/j.1365-2249.1992.tb02971.x.

Abstract

The neuroendocrine polypeptide hormone beta-endorphin (beta-END), which is released from various tissues including the anterior pituitary gland and cells of the immune system, has recently been implicated as having an immunoregulatory role. We used a radioimmunoassay to measure beta-END levels in circulating mononuclear leucocytes from normal subjects and patients with various rheumatic diseases. Levels of beta-END in leucocytes from patients were lower than in leucocytes from healthy subjects (P less than 0.001). Whereas levels of beta-END in leucocytes from patients with the various rheumatic disorders were not significantly different, an inverse correlation was found between beta-END levels in leucocytes and expression of rheumatoid factor (P less than 0.025) and erythrocyte sedimentation rate (P less than 0.025). This study demonstrates decreased content of beta-END in cells of the immune system related to parameters of inflammatory activity in rheumatic diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Sedimentation
  • C-Reactive Protein / metabolism
  • Humans
  • Immunoassay
  • Leukocytes, Mononuclear / metabolism*
  • Rheumatic Diseases / physiopathology*
  • Rheumatoid Factor / analysis
  • beta-Endorphin / blood*

Substances

  • beta-Endorphin
  • C-Reactive Protein
  • Rheumatoid Factor